Long-term comparative results of C0 and C2 monitoring of CyA in renal transplanted patients

Renal Failure

Volumn 27, Issue 4, 2005, Pages 409-413

  Paydaş, Saime ^a,b   Balal, M ^a   Sertdemir, Y ^a   Seyrek, N ^a   Karayaylah, I ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

C0 C2 monitoring; Cyclosporine; Renal transplantation

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN A; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; CADAVER DONOR; CHOLESTEROL BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MONITORING; FEMALE; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; CYCLOSPORINE; DRUG MONITORING; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEMODYNAMIC PROCESSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROBABILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TRANSPLANTATION IMMUNOLOGY;

EID: 22244472663     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-65330     Document Type: Article

References (9)

1. 2 monitoring: a review. Transplantation 2002, 73 (9), 3-11.
2. Shidban, H.; Mendez, R. Cyclosporine and tacrolimus. In Textbook of Nephrology, 4th Ed.; Massry, S.G., Glassock, R.J., Eds.; Lippincott Williams and Willkins: Philadelphia, 2001; 1627-1636.
3. 2 monitoring strategy for optimizing cyclosporine immunosuppression from Neoral formulation. BioDrugs 2001, 15, 279-290.
4. Kahan, B.D. Overview: individualization of cyclosporine therapy using pharmacokinetic and pharmocodynamic parameters. Transplantation 1985, 40, 457-476.
5. Lindholm, A.; Kahan, B.D. Influence of cyclosporine pharmacokinetics, trough concentration, and AUC monitoring on outcomes after kidney transplantation. Clin. Pharmacol. Ther. 1993, 54, 205-218.
6. Kahan, B.D.; Welsh, M.; Schoenberg, L. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic allograft rejection. Transplantation 1996, 62, 599-606.
7. 2 monitoring of cyclosporine microemulsion. Transplantation 2003, 76 (6), 903-908.
8. 2 cyclosporine levels monitoring in renal transplantation. Transplant. Proc. 2003, 35, 1072-1073.
9. Ojo, A.O.; Hanson, J.A.; Wolfe, R.A. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000, 57, 307.